Abstract: The present disclosure relates to a method of prognosing and predicting breast cancer recurrence in patients, More particularly, the present disclosure relates to a method of prognosing which stratifies early stage ER+/PR+ and Her2? breast cancer patients with invasive ductal/lobular carcinoma of the breast into low risk or high risk for breast cancer recurrence by employing an IHC based assay which assesses or measures expression of a combination of 5 biomarkers and by employing a histopathological analysis which assesses 3 clinical prognostic parameters. The present disclosure also relates to a combination of 5 biological markers and 3 clinical prognostics markers employed in the method for prognosis of breast cancer, a kit/test comprising the antibodies against said markers for said prognosis and an IHC based assay system comprising said markers.
Abstract: The present disclosure relates to a combination of biological markers for identification of prognosis of cancer. The present disclosure further relates to a method of identifying the said markers, a method of predicting prognosis and a method of planning personalized treatment for cancer. The present disclosure further relates to a kit/test comprising the antibodies against/other methods of detecting said markers for the said prediction.